Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen
Brian Coleman • 10 Comments
Brian Coleman • 10 Comments
Tue, Aug. 2, 7:04 AM
Tue, May 10, 7:10 AM
Tue, Feb. 9, 8:40 AM
- Compugen (CGEN) Q4 results: Revenues: $8.3M (+25.8%); Operating Expense: $8M (+19.4%); Operating Loss: ($0.7M) (+36.4%); Net Loss: ($0.5M) (+66.7%); Loss Per Share: ($0.01) (+66.7%).
- FY2015 results: Revenues: $9.3M (-25.0%); Operating Expense: $28.6M (+33.6%); Operating Loss: ($20.9M) (-69.9%); Net Loss: ($20.2M) (-82.0%); Loss Per Share: ($0.40) (-53.8%); Quick Assets: $81.4M (+11.1%).
- No guidance given.
Tue, Feb. 9, 7:12 AM
- Compugen (NASDAQ:CGEN): Q4 EPS of -$0.01 beats by $0.10.
- Revenue of $8.31M (+26.9% Y/Y) beats by $4.98M.
Dec. 11, 2015, 9:16 AM
Dec. 11, 2015, 9:04 AM
- Compugen (NASDAQ:CGEN) earns its third preclinical milestone payment from Bayer HealthCare (OTCPK:BAYRY) pursuant to their cancer immunotherapy collaboration and license agreement inked on August 5, 2013. The partnership relates to the research, development and commercialization of cancer immunotherapies targeted to two Compugen-discovered immune checkpoint regulators. This milestone, $7.8M, relates to the CGEN-15001T program, which has now been transferred to Bayer for advancement.
- The companies are continuing their collaboration to develop the second candidate, CGEN-15022.
- Under the terms of the agreement, Compugen has received an upfront payment of $10M and $15M in joint preclinical milestones. It is eligible to receive an additional $15M in preclinical milestones for CGEN-15022 and over $500M in potential milestones for both programs as well as mid-to-high single digit royalties on commercial sales.
- Previously: Compugen hits second preclinical milestone in Bayer collaboration (Oct. 14, 2014)
- Previously: Compugen achieves first milestone in Bayer collaboration (July 7, 2014)
- Previously: Compugen signs development deal with Bayer; shares soar (Aug. 5, 2013)
Nov. 3, 2015, 10:52 AM
- Compugen (CGEN -2.6%) Q3 results: Revenues: $0.2M (-88.2%); COGS: $0.2M (-71.4%); Operating Expense: $6.9M (+23.2%); Operating Loss: ($6.9M) (-50.0%); Net Loss: ($6.7M) (-24.1%); Loss Per Share: ($0.13) (-18.2%); Quick Assets: $74.3M (+1.4%).
- No guidance giiven.
Nov. 3, 2015, 7:08 AM
- Compugen (NASDAQ:CGEN): Q3 EPS of -$0.13 beats by $0.02.
- Revenue of $0.23M (-86.6% Y/Y) misses by $0.92M.
Aug. 4, 2015, 7:14 AM
- Compugen (NASDAQ:CGEN): Q2 EPS of -$0.14 misses by $0.01.
- Revenue of $0.22M (-88.8% Y/Y) misses by $1.58M.
Jun. 8, 2015, 8:39 AM
- Drug discovery firm Compugen (NASDAQ:CGEN) will unveil a new immune checkpoint target candidate, CGEN-15029, today at its Analyst and Investor Day in New York City. The affair will start at 9:00 am ET.
- Initial validation studies show that CGEN-15029 expression in T cells inhibits their activation by melanoma cells which is consistent with its tumor suppressive role.
- The company will also present its new computational infrastructure called LINKS, an in silico platform designed for the comprehensive and comparative assessment of drug targets.
May 5, 2015, 7:42 AM
- Compugen (NASDAQ:CGEN): Q1 EPS of -$0.12 beats by $0.01.
- Revenue of $0.51M (-76.1% Y/Y) misses by $0.97M.
Mar. 19, 2015, 9:59 AM
- Citing the need for more space, Tel Aviv, Israel-based Compugen (CGEN +0.4%) plans to move to new facilities by the end of the year, located ~12 miles away in the Azrieli Holon Business Center. The move will double the available space for the firm's corporate office and laboratories.
Feb. 10, 2015, 9:16 AM
Feb. 10, 2015, 7:16 AM
- Compugen (NASDAQ:CGEN): Q4 EPS of -$0.03 beats by $0.08.
- Revenue of $6.55M (+268.0% Y/Y) beats by $2.85M.
- Shares are up 8% premarket on increased volume.
Feb. 3, 2015, 7:45 AM
- Compugen (NASDAQ:CGEN) will report Q4 and full-year results on February 10 before the open. The conference call will begin at 10:00 am ET.
- Consensus views for Q4 and 2014 are losses per share of ($0.11) and ($0.31) on revenues of $3.7M and $7.6M, respectively.
Dec. 18, 2014, 7:58 AM
- Compugen (NASDAQ:CGEN) enters into a multi-year research collaboration with Johns Hopkins University, School of Medicine, to evaluate novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. The work will include the candidates' differentiation profile compared to known checkpoints and their potential to serve as monotherapy or in combination with other treatments.
- Specific terms of the partnership are undisclosed.